Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the development and commercialization of therapies. The company is engaged in complement inhibition and has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria, as well as the complement inhibitor to treat atypical hemolytic uremic syndrome and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In addition, the company has two enzyme replacement therapies for patients with metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.
  • TickerALXN
  • ISINUS0153511094
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Bispecifics Breaking Out in 2020

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Bispecifics Breaking Out in 2020

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kevin Huang

Alexion Pharmaceuticals, Inc.

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

Kevin Huang

Alexion Pharmaceuticals, Inc.

ValuEngine Rating and Forecast Report for ALXN

ValuEngine Rating and Forecast Report for ALXN

MarketLine Department

MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's MorphoSys AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by MorphoSys AG since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlight...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Upgrading Health Care to Overweight Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. • Sector Relative Strength Rankings & Weighting Recommendations. We are upgrading Health Care to overweight. We initially suggested adding exposure to the Sector in late-October as biotech (IBB, XBI) and pharma (PJP, PPH, XPH) stocks were making bullish price and RS reversals. Strength has permeated throughout the Sector ever since, and decisive RS bottoms for cap-weighted (XLV), equal-weighte...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch